Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

A commission proposed a new definition of obesity focused on how excess fat affects the body, rather than assessing body mass ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...

Comprehensive study exposes critical health risks of obesity, including diabetes, heart disease, and cancer, while offering ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...